Thromb Haemost 1972; 27(01): 107-113
DOI: 10.1055/s-0038-1649345
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Limitations of the Activated Partial Thromboplastin Time for Determination of Plasma Heparin Concentration and Half-Life in Human Subjects

G Baele
1   Department of Internal Medicine, University of Ghent, Belgium
,
M De Broe
1   Department of Internal Medicine, University of Ghent, Belgium
,
G. A De Weerdt
1   Department of Internal Medicine, University of Ghent, Belgium
,
S Ringoir
1   Department of Internal Medicine, University of Ghent, Belgium
,
F Barbier
1   Department of Internal Medicine, University of Ghent, Belgium
› Author Affiliations
Further Information

Publication History

Publication Date:
29 June 2018 (online)

Summary

In vivo heparin concentrations and half-life were estimated in 20 human subjects, after a single intravenous injection.

The method, used for heparin determination, is based on the activated partial thromboplastin time. The test plasmas are diluted in plasma of the same subject obtained before heparin administration. In this way the heparin concentrations are reduced to measurable levels between 0.1 I. U./ml and 0.8 I. U./ml. Indeed a linear relationship between log activated partial thromboplastin time and heparin concentrations from 0.1 to 0.8 I. U./ml can be computed. Different half-lives were found in 13 of the 20 subjects examined when different dilution factors were used. This seems an important limitation for the examination of the pharmacokinetics of heparin.

 
  • References

  • 1 Blombäck B, Blombäck M, Olsson P, William-Olsson G, Senning A. Determination of heparin level of the blood. Some observations on heparin elimination and correlation between heparin level and clotting time after intravenous injection. Acta chir. scand Suppl. 245: 259 1959;
  • 2 Deykin D. The use of heparin. New Engl. J. Med 280: 937 1969;
  • 3 De Potter E, Offner-Van den Berghe C. L’emploi d’un nouveau test de contrôle de la coagulation intrinsèque. Actahémat 28: 370 1962;
  • 4 Eiber H. B, Danishefsky I. Fate of injected heparin. Trans. Amer. Soc. Artif. Internal Organs 04: 152 1958;
  • 5 Estes J. W, Pelikan E. W, Krüger-Thiemer E. A retrospective study of the pharmacokinetics of heparin. Clin, pharmacol. Ther 10: 329 1969;
  • 6 Estes J. W. Kinetics of the anticoagulant effect of heparin. J. Amer. med. Assoc 212: 1492 1970;
  • 7 Griffith G. G, Nichols Jr. G, Asher J. D, Flanagan B. Heparin osteoporosis. J. Amer, med. Assoc 193: 85 1965;
  • 8 Hougie G. Letter to the editor: The Lee and White test for coagulation time. Amer. J. clin. Path 36: 537 1961;
  • 9 Jaffe M. D, Willis P. W. Multiple fractures associated with long-term sodium heparin therapy. J. Amer. med. Assoc 193: 152 1965;
  • 10 Majoor C. L. H. Heparin and osteoporosis. Lancet II: 641 1965;
  • 11 Marder V. J. A simple technique for the measurement of plasma heparin concentration during anticoagulant therapy. Thrombos. Diathes. haemorrh. (Stuttg) 24: 230 1970;
  • 12 Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin. An experimental study on dogs and humans. Acta med. scand 173: 619 1963;
  • 13 Pitney W. R, Pettit J. E, Amstrong L. Control of heparin therapy. Brit. med. J 04: 139 1970;
  • 14 Thurnherr N, Thölen H, Duckert F. Quantitative heparin determination and periodic extra - corporeal dialysis. Helv. med. Acta 04: 334 1966;